ESPE Abstracts (2022) 95 P1-522

ESPE2022 Poster Category 1 Growth and Syndromes (85 abstracts)

Positive impact of the TuiTek® patient support programme on caregivers of patients receiving treatment for growth hormone deficiency in Argentina

Micaela Sordelli 1 , Matías Debicki 1 , Judit Gonzalez 1 , Ana María Sosa 1 , Leopoldo Hernán Cejas 1 , Romina Ginaca 1 , Amrit Jheeta 2 , Sumaira Malik 2 , Ekaterina Koledova 3 & Aria Assefi 1

1Merck S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Buenos Aires, Argentina; 2Atlantis Healthcare, London, United Kingdom; 3Global Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany

Background: Good adherence to recombinant human growth hormone (r-hGH) is crucial to achieve optimal growth outcomes in children with GH deficiency (GHD). Controlling factors that negatively impact adherence is difficult in clinical practice. In order to obtain a better understanding of caregiver behaviour, an Argentinian patient support programme (PSP) implemented TuiTek®, a personalised programme comprising behavioural change training, call guides and resource packs. It addresses four key dimensions commonly faced by caregivers: 1) disease and treatment coherence, 2) emotional burden, 3) treatment-related anxiety and 4) self-administration, and offers tools and strategies to improve each of these dimensions in cases where scores fall outside of the expected limits.

Aim: To evaluate the impact of the TuiTek® PSP on caregivers’ perceptions of r-hGH adherence and treatment options in patients with GHD over three months in Argentina.

Methods: Nurses associated with the PSP delivered a personalisation questionnaire based on feedback received from 76 caregivers of patients with GHD who were undergoing r-hGH treatment using the easypod® auto-injector device in Argentina; risk assessment scores were established using a 5-point rating scale. Caregivers who were classified as ‘high risk’ in at least one of the four dimensions (defined as a score of 1–3 for disease and treatment coherence and self-administration; 3–5 for emotional burden and treatment-related anxiety) at the start of the programme received bi-weekly personalised telephone interventions and follow-up calls from PSP nurses over the course of three months. The caregivers were then reclassified in each of the four dimensions post-intervention. The Wilcoxon-sum rank test was used to analyse questionnaire-based scoring patterns between baseline and follow-up; P<0.05 was considered statistically significant.

Results: Of the 460 caregivers enrolled in the study, 170 (37%) were initially categorised as ‘high risk’ and 290 (63%) as ‘low risk’. Of the caregivers in the ‘high risk’ group, 76 completed the entire three-month programme. Statistically significant differences (P<0.05) in questionnaire scores between baseline and follow-up were observed for ‘disease and treatment coherence’, ‘emotional burden’, ‘self-administration’ and ‘treatment-related anxiety’. Over the three month period, the percentage of caregivers considered to be at ‘high risk’ regarding both ‘disease and treatment coherence’ and ‘self-administration’ decreased by 100%. ‘Treatment-related anxiety’ was reduced by 67,5%.

Conclusion: The TuiTek® PSP enabled nurses to provide more effective support for caregivers. This intervention could help caregivers to improve and maintain their child’s adherence to r-hGH therapy with the goal of optimising clinical outcomes.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.